Prognostic Factors in Advanced Non-Small Cell Lung Cancer Patients Treated with Immunotherapy

被引：5

作者：

Rocco, Danilo ^{[1
]}

Della Gravara, Luigi ^{[2
]}

Ragone, Angela ^{[3
]}

Sapio, Luigi ^{[2
]}

Naviglio, Silvio ^{[2
]}

Gridelli, Cesare ^{[4
]}

机构：

[1] AORN Colli Monaldi, Dept Pulm Oncol, I-80131 Naples, Italy

[2] Univ Campania Luigi Vanvitelli, Dept Precis Med, I-80138 Naples, Italy

[3] Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany

[4] SG Moscati Hosp, Div Med Oncol, I-83100 Avellino, Italy

来源：

CANCERS | 2023年 / 15卷 / 19期

关键词：

NSCLC; immunotherapy; prognostic factors; PD-L1; TMB; NLR; TILs; gut microbiota; concomitant medications; INDUCED TNF RECEPTOR; BODY-MASS INDEX; ANTI-GITR MAB; T-CELLS; PROTEIN EXPRESSION; ANTITUMOR IMMUNITY; LYMPHOCYTE RATIO; NSCLC PATIENTS; PD-1; PATHWAYS; WEIGHT-LOSS;

D O I：

10.3390/cancers15194684

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Simple Summary Immunotherapy in the form of Immune Checkpoint Inhibitors which currently represent one of the staples of advanced Non-Small Cell Lung Cancer treatment. However, as of today, no prognostic factors are taken in account to shape immunotherapy-treated patient selection and management according to the most authoritative international guidelines. Therefore, the identification and evaluation of possible prognostic factors in this subset of patients represent an extremely interesting and relevant topic.Abstract Taking into account the huge epidemiologic impact of lung cancer (in 2020, lung cancer accounted for 2,206,771 of the cases and for 1,796,144 of the cancer-related deaths, representing the second most common cancer in female patients, the most common cancer in male patients, and the second most common cancer in male and female patients) and the current lack of recommendations in terms of prognostic factors for patients selection and management, this article aims to provide an overview of the current landscape in terms of currently available immunotherapy treatments and the most promising assessed prognostic biomarkers, highlighting the current state-of-the-art and hinting at future challenges.

引用

页数：17

共 150 条

[21] Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy [J].

Cortellini, Alessio ;

Di Maio, Massimo ;

Nigro, Olga ;

Leonetti, Alessandro ;

Cortinovis, Diego L. ;

Aerts, Joachim G. J., V ;

Guaitoli, Giorgia ;

Barbieri, Fausto ;

Giusti, Raffaele ;

Ferrara, Miriam G. ;

Bria, Emilio ;

D'Argento, Ettore ;

Grossi, Francesco ;

Rijavec, Erika ;

Guida, Annalisa ;

Berardi, Rossana ;

Torniai, Mariangela ;

Sforza, Vincenzo ;

Genova, Carlo ;

Mazzoni, Francesca ;

Garassino, Marina Chiara ;

De Toma, Alessandro ;

Signorelli, Diego ;

Gelibter, Alain ;

Siringo, Marco ;

Marchetti, Paolo ;

Macerelli, Marianna ;

Rastelli, Francesca ;

Chiari, Rita ;

Rocco, Danilo ;

Della Gravara, Luigi ;

Inno, Alessandro ;

Michele, De Tursi ;

Grassadonia, Antonino ;

Di Marino, Pietro ;

Mansueto, Giovanni ;

Zoratto, Federica ;

Filetti, Marco ;

Santini, Daniele ;

Citarella, Fabrizio ;

Russano, Marco ;

Cantini, Luca ;

Tuzi, Alessandro ;

Bordi, Paola ;

Minuti, Gabriele ;

Landi, Lorenza ;

Ricciardi, Serena ;

Migliorino, Maria R. ;

Passiglia, Francesco ;

Bironzo, Paolo .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (04)

[22] Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation [J].

Cortellini, Alessio ;

Ricciuti, Biagio ;

Tiseo, Marcello ;

Bria, Emilio ;

Banna, Giuseppe L. ;

Aerts, Joachim G. J., V ;

Barbieri, Fausto ;

Giusti, Raffaele ;

Cortinovis, Diego L. ;

Migliorino, Maria R. ;

Catino, Annamaria ;

Passiglia, Francesco ;

Torniai, Mariangela ;

Morabito, Alessandro ;

Genova, Carlo ;

Mazzoni, Francesca ;

Di Noia, Vincenzo ;

Signorelli, Diego ;

Gelibter, Alain ;

Occhipinti, Mario Alberto ;

Rastelli, Francesca ;

Chiari, Rita ;

Rocco, Danilo ;

Inno, Alessandro ;

De Tursi, Michele ;

Di Marino, Pietro ;

Mansueto, Giovanni ;

Zoratto, Federica ;

Grossi, Francesco ;

Filetti, Marco ;

Pizzutilo, Pamela ;

Russano, Marco ;

Citarella, Fabrizio ;

Cantini, Luca ;

Targato, Giada ;

Nigro, Olga ;

Ferrara, Miriam G. ;

Buti, Sebastiano ;

Scodes, Simona ;

Landi, Lorenza ;

Guaitoli, Giorgia ;

Della Gravara, Luigi ;

Tabbo, Fabrizio ;

Ricciardi, Serena ;

De Toma, Alessandro ;

Friedlaender, Alex ;

Petrelli, Fausto ;

Addeo, Alfredo ;

Porzio, Giampiero ;

Ficorella, Corrado .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)

[23] A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable [J].

Cortellini, Alessio ;

Bersanelli, Melissa ;

Buti, Sebastiano ;

Cannita, Katia ;

Santini, Daniele ;

Perrone, Fabiana ;

Giusti, Raffaele ;

Tiseo, Marcello ;

Michiara, Maria ;

Di Marino, Pietro ;

Tinari, Nicola ;

De Tursi, Michele ;

Zoratto, Federica ;

Veltri, Enzo ;

Marconcini, Riccardo ;

Malorgio, Francesco ;

Russano, Marco ;

Anesi, Cecilia ;

Zeppola, Tea ;

Filetti, Marco ;

Marchetti, Paolo ;

Botticelli, Andrea ;

Cappellini, Gian Carlo Antonini ;

De Galitiis, Federica ;

Vitale, Maria Giuseppa ;

Rastelli, Francesca ;

Pergolesi, Federica ;

Berardi, Rossana ;

Rinaldi, Silvia ;

Tudini, Marianna ;

Silva, Rosa Rita ;

Pireddu, Annagrazia ;

Atzori, Francesco ;

Chiari, Rita ;

Ricciuti, Biagio ;

De Giglio, Andrea ;

Iacono, Daniela ;

Gelibter, Alain ;

Occhipinti, Mario Alberto ;

Parisi, Alessandro ;

Porzio, Giampiero ;

Fargnoli, Maria Concetta ;

Ascierto, Paolo Antonio ;

Ficorella, Corrado ;

Natoli, Clara .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7

[24] Plasma Biomarkers and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: New Tools for Better Patient Selection? [J].

Costantini, Adrien ;

Kamga, Paul Takam ;

Dumenil, Coraline ;

Chinet, Thierry ;

Emile, Jean-Francois ;

Leprieur, Etienne Giroux .

CANCERS, 2019, 11 (09)

[25] Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab [J].

Costantini, Adrien ;

Julie, Catherine ;

Dumenil, Coraline ;

Helias-Rodzewicz, Zofia ;

Tisserand, Julie ;

Dumoulin, Jennifer ;

Giraud, Violaine ;

Labrune, Sylvie ;

Chinet, Thierry ;

Emile, Jean-Francois ;

Leprieur, Etienne Giroux .

ONCOIMMUNOLOGY, 2018, 7 (08)

[26] T Follicular Helper Cell Differentiation, Function, and Roles in Disease [J].

Crotty, Shane .

IMMUNITY, 2014, 41 (04) :529-542

[27] Impact of proton-pump inhibitors on the efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis [J].

Dar, Sophia ;

Merza, Nooraldin ;

Rahim, Mehek ;

Qatani, Ahmad ;

Varughese, Tony ;

Mohammad, Asna ;

Masood, Fahad ;

Reza, Fizza ;

Wan, Schuchen ;

Almas, Talal ;

Ellahi, Aayat ;

Ligresti, Rosario .

ANNALS OF MEDICINE AND SURGERY, 2022, 78

[28] The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors [J].

Davis, Andrew A. ;

Patel, Vaibhav G. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01)

[29] The prognostic value of weight and body composition changes in patients with non-small-cell lung cancer treated with nivolumab [J].

Degens, Juliette H. R. J. ;

Dingemans, Anne-Marie C. ;

Willemsen, Anna C. H. ;

Gietema, Hester A. ;

Hurkmans, Daan P. ;

Aerts, Joachim G. ;

Hendriks, Lizza E. L. ;

Schols, Annemie M. W. J. .

JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2021, 12 (03) :657-664

[30] PROGNOSTIC EFFECT OF WEIGHT-LOSS PRIOR TO CHEMOTHERAPY IN CANCER-PATIENTS [J].

DEWYS, WD ;

BEGG, C ;

LAVIN, PT ;

BAND, PR ;

BENNETT, JM ;

BERTINO, JR ;

COHEN, MH ;

DOUGLASS, HO ;

ENGSTROM, PF ;

EZDINLI, EZ ;

HORTON, J ;

JOHNSON, GJ ;

MOERTEL, CG ;

OKEN, MM ;

PERLIA, C ;

ROSENBAUM, C ;

SILVERSTEIN, MN ;

SKEEL, RT .

AMERICAN JOURNAL OF MEDICINE, 1980, 69 (04) :491-497

← 1 2 3 4 5 6 7 8 9 10 →